Affordable Access

deepdyve-link
Publisher Website

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis.

Authors
  • Samuelson Bannow, Bethany T1
  • Warad, Deepti2
  • Jones, Curtis3
  • Pechauer, Shannon4
  • Curtis, Brian R5
  • Bougie, Daniel W5
  • Sharma, Ruchika6
  • Grill, Diane7
  • Redman, Mary8
  • Khalighi, Parisa Rose9
  • Leger, Rachel2
  • Pruthi, Rajiv K2
  • Chen, Dong2
  • Sabath, Daniel10
  • Aster, Richard H11
  • Garcia, David10
  • Padmanabhan, Anand2
  • 1 Oregon Health & Science University, PORTLAND, Oregon, United States. , (United States)
  • 2 Mayo Clinic, Rochester, Minnesota, United States. , (United States)
  • 3 Retham Technologies, Wauwatosa, Wisconsin, United States. , (United States)
  • 4 BloodCenter of Wisconsin, Wauwatosa, Wisconsin, United States. , (United States)
  • 5 Versiti, Milwaukee, Wisconsin, United States. , (United States)
  • 6 Versiti, Medical College of Wisconsin, Milwaukee, Wisconsin, United States. , (United States)
  • 7 Mayo Clinic.
  • 8 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States. , (United States)
  • 9 University of Colorado, Aurora, Colorado, United States. , (United States)
  • 10 University of Washington, Seattle, Washington, United States. , (United States)
  • 11 Versiti-Blood Research Institute, Milwaukee, Wisconsin, United States. , (United States)
Type
Published Article
Journal
Blood
Publisher
American Society of Hematology
Publication Date
Sep 08, 2020
Identifiers
DOI: 10.1182/blood.2020008195
PMID: 32898858
Source
Medline
Language
English
License
Unknown

Abstract

Heparin-induced thrombocytopenia (HIT) is a life-threatening, pro-thrombotic, antibody-mediated disorder. To maximize the likelihood of recovery, early and accurate diagnosis is critical. Widely available HIT assays such as the Platelet Factor 4-Heparin ELISAs lack specificity, and the "gold standard" C14-labeled serotonin release assay (SRA) is of limited value for early patient management due to availability only through reference laboratories. Recent studies demonstrate that "pathogenic" HIT antibodies selectively activate PF4-treated platelets and that a technically simpler assay, the PF4-dependent P-selectin Expression Assay (PEA), may provide an option for rapid and conclusive results. Four hundred and nine consecutive adults suspected of HIT were classified as disease-positive, -negative or -indeterminate based upon predefined criteria that combined 4Ts scores and HIT ELISA results. Patients deemed "HIT-indeterminate" were considered disease-negative in the primary analysis and disease-positive in a sensitivity analysis. The ability of PEA and SRA to identify patients judged to have HIT was compared using receiver operating characteristic curve statistics. Using these predefined criteria, the diagnostic accuracy of PEA was high (Area under the curve [AUC] of 0.94; 0.87-1.0, 95% CI) and similar to that of SRA (0.91; 0.82-1.0, 95% CI). In sensitivity analysis, the AUCs of PEA and SRA were also similar at 0.88 (0.78-0.98, 95% CI) and 0.86 (0.77-0.96, 95% CI), respectively. The PEA, a technically simple non-radioactive assay that uses ~20-fold fewer platelets compared to the SRA had high accuracy for diagnosing HIT. Widespread use of the PEA may facilitate timely and more effective management of patients with suspected HIT. Copyright © 2020 American Society of Hematology.

Report this publication

Statistics

Seen <100 times